Status: Recruiting
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
This is a single-center, single-arm, open-label, exploratory study to determine the safety, tolerability, feasibility, and preliminary anti-tumor activity of anti-CD19-CAR-T cells in subjects with relapsed/refractory (r/r) B-cell malignancies. This study plans to enroll patients with relapsed/refractory CD19-positive B-cell malignancies, who will receive a single infusion of anti-CD19-CAR-T cells after screening, PBMC collection, and lymphodepleting chemotherapy.
Participants needed: 9
Trial details
Phase: Early Phase 1Age: 14-70Biological sex: AllType: InterventionalSponsor: Shanghai First Song Biotechnology Co., LTDUpdated: Feb 28, 2025Locations: 1
Eligibility criteria
Patient able to provide written informed consent; parent or guardian of minor pa... [+20]
CNS-3, defined as detectable tumor cells in cerebrospinal fluid (CSF) with ≥ 5 w... [+35]